文献速递腹部CT

双能CT肿瘤-胰腺界面强化梯度可改善胰腺导管腺癌预后评估

Pancreatic Ductal Adenocarcinoma: Interface Enhancement Gradient Measured on Dual-Energy CT Images Improves Prognostic Evaluation.
PubMed 文献 · Radiol Imaging Cancer · 2020-07-17

该回顾性研究纳入158例初治胰腺导管腺癌患者,在双能CT胰腺实质期70-keV、52-keV及碘密度图上测量肿瘤-胰腺界面强化梯度(delta),并结合门静脉期常规CT评估其预后价值。结果显示,高delta(≥40 HU)患者总生存期显著缩短,早期PDAC为13.5个月 vs 23.3个月(HR 1.87),晚期PDAC为10.8个月 vs 18.0个月(HR 2.1);主观边界清晰度评分在碘密度图和52-keV图像上观察者间一致性最高(κ分别为0.73和0.60)。

要点

  • 双能CT测量的肿瘤-胰腺界面强化梯度高(≥40 HU)与PDAC患者总生存期缩短相关。

关键影像表现/征象

  • 在胰腺实质期70-keV、52-keV和碘密度图及门静脉期常规CT图像上记录肿瘤核心、肿瘤边界、胰腺-肿瘤交界、非肿瘤胰腺和主动脉的感兴趣区。
  • 计算肿瘤-胰腺界面强化梯度(delta),高delta定义为≥40 HU(基于70-keV胰腺实质期或常规门静脉期图像)。
  • 更多边界清晰的肿瘤患者总生存期更短(定性视觉评分)。

诊断标准与关键数值

  • 高delta阈值≥40 HU(基于70-keV胰腺实质期或常规门静脉期图像),通过ROC分析结合逻辑回归以最高Youden指数确定。
  • 主观delta评分的观察者间一致性κ值:碘密度图0.73,52-keV图像0.60。

临床应用与阅片要点

  • 在胰腺双能CT胰腺实质期测量肿瘤-胰腺界面强化梯度(delta),高delta(≥40 HU)提示预后较差。
  • 主观评估肿瘤边界清晰度时,优先使用碘密度图和52-keV模拟单能图像以获得更好的一致性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the prognostic value of differential enhancement on baseline dual-energy CT images in patients with treatment-naive pancreatic ductal adenocarcinoma (PDAC), with a focus on tumor-host interface characterization.

MATERIALS AND METHODS: This was a retrospective, institutional review board-approved, Health Insurance Portability and Accountability Act-compliant study of 158 consecutive adult patients (mean age, 68 years; age range, 40.9-88.9 years; 50% women) with histopathologically proven, treatment-naive PDAC, who had undergone multiphasic pancreatic dual-energy CT from December 2011 to March 2017. Regions of interest in tumor core, tumor border, pancreas border with tumor, nontumoral pancreas, and aorta were recorded on pancreatic parenchymal phase (PPP) dual-energy CT 70-keV, 52-keV, and iodine material density (MD) images, plus portal venous phase (PVP) conventional CT images. Enhancement gradient (delta) across the tumor-pancreas interface was calculated. Delta was evaluated combining the dual-energy CT values with the PVP values and as individual predictors. Receiver operating characteristic analysis with logistic regression was used to determine the optimal cut point for each dual-energy CT delta to predict disease outcome based on highest Youden index. Survival curves were generated using Kaplan-Meier method, and comparison between two independent groups (high and low delta) was evaluated with log-rank test. Clinical outcomes included overall survival and distant metastasis-free survival. Three independent blinded radiologists visually scored tumor conspicuity (subjective delta score) on a 1-5 scale, and agreement was evaluated with κ statistic.

RESULTS: Ninety-three patients had advanced stage (50 locally advanced and 43 metastatic) and 65 had lower stage (48 resectable and 17 borderline resectable) tumors. Patients with high delta tumors (≥ 40 HU) on either 70-keV PPP images or conventional PVP images had significantly shorter overall survival compared with those with low delta tumors (< 40 HU) in both early stage PDAC (13.5 months vs 23.3 months; hazard ratio [HR], 1.87; 95% confidence interval [CI]: 1.01, 3.5; P = .04) and advanced stage PDAC (10.8 months vs 18.0 months; HR, 2.1; 95% CI: 1.28, 3.6; P = .003). Qualitative visual scoring of tumor conspicuity also showed shorter overall survival in patients with more conspicuous tumors. Highest interreader agreement for subjective delta score was 0.73 and 0.60 using iodine MD and 52-keV images, respectively.

CONCLUSION: Increased quantitative and qualitative border conspicuity (high delta) is associated with shorter survival in patients with PDAC. Agreement on the subjective qualitative characterization of PDAC borders is best achieved using iodine MD and lower-energy simulated monoenergetic images at pancreatic protocol dual-energy CT.Keywords: Abdomen/GI, CT, CT-Dual Energy, CT-Quantitative, PancreasSupplemental material is available for this article.© RSNA, 2020.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Amer AM, Li Y, Summerlin D, et al. Pancreatic Ductal Adenocarcinoma: Interface Enhancement Gradient Measured on Dual-Energy CT Images Improves Prognostic Evaluation. Radiol Imaging Cancer. 2020. PMID: 33778722. doi:10.1148/rycan.2020190074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。